ArticlePhytochemistry2011
Pitipeptolides C-F, antimycobacterial cyclodepsipeptides from the marine cyanobacterium Lyngbya majuscula from Guam.
Article in Phytochemistry, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 85 citations in OpenAlex.
- Algal bioactive compounds for next-generation biopesticides: a multi-target resource for sustainable pest management.Environmental science and pollution research international · 2026Review
- Molecular Insights into Anabaenopeptin-Mediated Inhibition of Protein Tyrosine Phosphatase B in theACS omega · 2026Article
- Antimycobacterial peptides as natural therapeutics for tuberculosis: mechanisms and structural features.Frontiers in antibiotics · 2026Review
- Phycocompounds from Cyanobacteria: Exploring Synergistic Effects with Conventional Anticancer and Antimicrobial Properties.ACS omega · 2025Review
- Chemical diversity of cyanobacterial natural products.Natural product reports · 2025Review
- Marine Cyanobacteria: A Rich Source of Structurally Unique Anti-Infectives for Drug Development.Molecules (Basel, Switzerland) · 2024Review
- Nanosynthesis, phycochemical constituents, and pharmacological properties of cyanobacterium Oscillatoria sp.Naunyn-Schmiedeberg's archives of pharmacology · 2024Review
- Antimicrobial Peptides as Immunomodulators and Antimycobacterial Agents to Combat Mycobacterium tuberculosis: a Critical Review.Probiotics and antimicrobial proteins · 2023Review
- A Review of the Antimicrobial Properties of Cyanobacterial Natural Products.Molecules (Basel, Switzerland) · 2023Review
- Recent progression on phytochemicals and pharmacological properties of the filamentous cyanobacterium Lyngbya sp.Naunyn-Schmiedeberg's archives of pharmacology · 2023Review
- Marine Cyanobacterial Peptides in Neuroblastoma: Search for Better Therapeutic Options.Cancers · 2023Review
- Green Antimicrobials as Therapeutic Agents for Diabetic Foot Ulcers.Antibiotics (Basel, Switzerland) · 2023Review
- Absolute Stereochemistry Determination of Bioactive Marine-Derived Cyclopeptides by Liquid Chromatography Methods: An Update Review (2018-2022).Molecules (Basel, Switzerland) · 2023Review
- Antimicrobial peptides as drugs with double response againstFrontiers in microbiology · 2023Review
- Anti-Infective Secondary Metabolites of the Marine CyanobacteriumMarine drugs · 2022Review
- Laser Treatment Increases the Antimicrobial Efficacy of Cyanobacterial Extracts againstInternational journal of environmental research and public health · 2022Article
- Marine Cyclic Peptides: Antimicrobial Activity and Synthetic Strategies.Marine drugs · 2022Review
- Review of Cyanotoxicity Studies Based on Cell Cultures.Journal of toxicology · 2022Review
- Bifunctional Doscadenamides Activate Quorum Sensing in Gram-Negative Bacteria and Synergize with TRAIL to Induce Apoptosis in Cancer Cells.Journal of natural products · 2021Article
- Cyanobacteria as Natural Therapeutics and Pharmaceutical Potential: Role in Antitumor Activity and as Nanovectors.Molecules (Basel, Switzerland) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Pitipeptolides A (1) and B (2) are cyclic depsipeptides isolated from the marine cyanobacterium Lyngbya majuscula from Piti Bomb Holes, Guam. Additional analogues have now been isolated by revisiting larger collections of the same cyanobacterium. The four identified analogues, pitipeptolides C-F (3-6), are the tetrahydro analogue (3), an analogue with a lower degree of methylation (4) as well as two homologues (5 and 6) of pitipeptolide A. Their structures were elucidated using 2D NMR experiments, chiral HPLC analysis and comparison with pitipeptolide A. The identified analogues showed weaker cytotoxic activities compared to the two major parent compounds, pitipeptolides A (1) and B (2), against HT-29 colon adenocarcinoma and MCF7 breast cancer cells. On the other hand, pitipeptolide F (6) was the most potent pitipeptolide in a disc diffusion assay against Mycobacterium tuberculosis. The latter finding suggests that the structure of pitipeptolides could be optimized for selective antibacterial activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.